Within the React-EU project “reMIND” industrial and academic partners will industrialize and integrate four complementary techniques for the treatment of Alzheimer’s disease. The consortium consisits of Demcon, Micronit, Locsense, Scinus Cell Expansion, Universiteit Twente. Locsense contribution consists of monitoring the integrity of the blood-brain-barrier and potential treatment effectiveness. Currently there are no treatments available for Alzheimer’s disease. Upon the moment of diagnosis, millions of braincells have been damaged already. Within the reMIND project, regenerative therapies will be investigated as well as effectives of delivery of therapeutics to the brain. Available therapeutic candidates are incapable of permeation through the blood-brain-barrier. Conventional processes of developing new medicine involve animal tests, which are not a good predictor for effectiveness in humans. Within reMIND, the consortium will develop technologies that contribute to solving these issues.
The reMIND project is part-funded as part of the Union’s response to the COVID-19 pandemic.